# **Colonoscopy quality Perspective from outside North America**

#### Masau Sekiguchi, MD, PhD (masekigu@ncc.go.jp)

1. Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan 2. Division of Screening Technology, National Cancer Center Institute for Cancer Control, Tokyo, Japan



WEO The voice of world endoscopy





## **Disclosure of Conflicts of Interest**

## There are no conflicts of interest to be disclosed.







## 1. Current Situation of CRC screening and Colonoscopy in Asia

### 2. Possibly Important Factors for Colonoscopy Quality from the Asian (Japanese) perspective







## 1. Current Situation of CRC screening and Colonoscopy in Asia

## 2. Possibly Important Factors for Colonoscopy Quality from the Asian (Japanese) perspective





## **Colorectal Cancer Screening in Asia**

Country/Region	Launch Year	Age of Target Population (years old)	Screen Popula Scr	ing Test in tion-based eening
Japan	1992	≥40	FIT	Annual, 2 day
South Korea	2004	≥50	FIT	Annual, 1 day
Taiwan	2004	50-74	FIT	Biannual, 1 day
Singapore	2011	≥50	FIT	Annual, 2 day
Hong Kong	2018 (pilot 2016)	50-75	FIT	Biannual, 1 day
Thailand	2017 (pilot 2014)	50-70	FIT	One time, 1 day

Ref) Lui RN, Wong SH, Ding NS, Sekiguchi M, Yu J, Ang TL, Yeoh KG, Chiu HM, Sung JJY. Is this the end of colonoscopy screening for colorectal cancer? An Asia-Pacific perspective. J Gastroenterol Hepatol. 2023; 38: 671-77.

Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan

 $\checkmark$  Total colonoscopy is used as the primary exam only in the opportunistic screening.



## **Colonoscopy for FIT+ in Population-based Screening in Asia**

<b>Country/Region</b>	Any su	special regulations for endoscopists ch as experience of colonoscopy?	Government Financial Support (Medical Reimbursement <i>etc.</i> )	Cost for a colonoscopy procedure (USD: exchange rate on April 23, 2024)
Japan	No	NO JGES has started the certification system Y requiring experience of ≥300 colonoscopies		100 (323-452 with polypectomy)
South Korea	No	Usually gastroenterologists and surgeons	Yes	<b>87</b> (145 with polypectomy)
Taiwan	No	Usually gastroenterologists and surgeons	Yes	125 for FIT+ (73 for others)
Singapore	No	Usually gastroenterologists and surgeons	Yes	954 (3083 with polypectomy)
Hong Kong	No	Gastroenterologist and General Surgeon	Yes	≈1276
Thailand	No	Usually certified surgeon or gastroenterologist with experience of ≥100 colonoscopies	Yes	(complicated)
	No nur Ref) Sekiguch Gastroentero	<b>rse endoscopists</b> i M, Westerberg M, Ekbom A, Hultcrantz R, Forsberg A (SCREESCO logy. 2023 Feb;164(2):293-295.e4.	). Based on p ). Han-Mo Cl Supakii Kh	personal communications with Drs. Wen-Feng hiu, Chang Mo Moon, Jonathan Lee Wei Jie, Ro omvilai. and Takahisa Matsuda.





## Management System of Colonoscopy Quality in Asia

<b>Country/Region</b>	Does guidel	s the country/region have its own ines or documents on colonoscopy quality indicators?	Nationwide standardized format for colonoscopy reports?	Nationwide andardized format for colonoscopy reports? Nationwide system of monitoring colonoscopy quality?		Nationwide feedback syst of colonosco quality to endoscopist
Japan	Yes	Colonoscopy screening and surveillance guidelines (JGES). Dig Endosc. 2021;33: 486-519.	No	No	No	No
South Korea	No	Referring to US guidelines	No	No	No	No
Taiwan	Yes	The Taiwan Guideline for CRC Screening. URL: https://www.dest.org.tw/DB/News/file/501-2.pdf	Yes (for population-based screening)	Yes (for population-based screening)	Yes (for population-based screening)	Yes (for population-basis screening)
Singapore	No	Referring to US guidelines	No	No	No	No
Hong Kong	No	Referring to US and AP guidelines	No	No	No	No
Thailand	No		No	No	No	No



Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan

Based on personal communications with Drs. Wen-Feng Hsu, Han-Mo Chiu, Chang Mo Moon, Jonathan Lee Wei Jie, Rashid N Lui, Supakij Khomvilai, and Takahisa Matsuda.







The flow chart of Taiwan Colorectal **Cancer Screening Program** 

Quality assessment of colonoscopy





able 3. Benchmarks of colonoscopy quality indicators in the Taiwan Colorectal Cancer         Screening Program       Ref) The Taiwan Guideline for CRC Screening.         Indicator       Criteria					
Indicator	Criteria				
Rate of adequate bowel preparation (Aronchick scale: good or above)	≥ 90%				
Cecal intubation rate	≥ 95%				
Withdrawal time: 6 minutes or more	≥ 90%				
Adenoma detection rate (for FIT+)	≥ 40%				
Complete polypectomy rate	≥ 90%				
Sample retrieval rate	≥ 90%				



**Table 3.** Benchmarks of colonoscopy quality indicators in the Taiwan Colorectal Cancer
 Screening Program Ref) The Taiwan Guideline for CRC Screening.

Indicator			Crite
Rate of adequate bowel preparation (Aronchick scale: good or abo	ove)		≥ 90
Cecal intubation rate			≥ 95
Withdrawal time: 6 minutes or more			≥ 90
Adenoma detection rate (for FIT+)			≥ 40
Complete polypectomy rate		100.0	
Sample retrieval rate	-		
	-	80.0	
	(%)	<b>60 0</b>	
	I CIR	60.0	
	R anc	40.0	4
	AD		
		20.0	
		0.0	2004 2

Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan

#### *Courtesy of Dr. Wen-Feng HSU (National Taiwan University Hospital)*











Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan

#### *Courtesy of Prof. Han-Mo Chiu (National Taiwan University Hospital)*







Japan Gastroenterological Endoscopy Society (JGES) tries to establish the nationwide endoscopy database.

#### Japan Endoscopy Database (JED)

https://jedproject.jges.net/



Ref) Matsuda K, Tanaka K, Fujishiro M, et al. Dig Endosc. 2018; 30: 5-19. Saito Y, Kodashima S, Matsuda T, et al. Dig Endosc. 2022; 34: 144-152. etc.

Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan

- JGES initiated the system of "certified endoscopists" for screening endoscopies" in 2022.
- <u>Requirements for certified endoscopists</u> who can perform screening colonoscopy
  - Experience of  $\geq 300$  colonoscopy procedures (From 2025,  $\geq$ 500)
  - Hands-on seminars and lectures  $\bullet$

etc.









Ref) Kawamura T, Sekiguchi M, et al. Dig Endosc. 2023; 35: 615-24. Kawamura T, Sekiguchi M, et al. Dig Endosc. 2024; 36: 51-8.

of colonoscopy and corresponding pathology results.

Data from adult individuals who had undergone colonoscopy at eight participating institutions across Japan between 2010 and 2020 were analyzed.

Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan

✓ The "J-SCOUT" study is a multicenter observational study in Japan aiming to elucidate factors affecting colonoscopy outcomes by using a large database that included findings















Ref) Kawamura T, Sekiguchi M, et al. Dig Endosc. 2023; 35: 615-24. Kawamura T, Sekiguchi M, et al. Dig Endosc. 2024; 36: 51-8.

186,293 cases of colonoscopy procedures performed for the study participants aged  $\geq$ 20 years at the eight participating institutions between April 2010 and March 2020 in the J-SCOUT study

Exclusion (with overlap in the following conditions)

 $\checkmark$  Cases of colonoscopy procedures performed within six months after the prior colonoscopy (n=31,533)  $\checkmark$  Cases of colonoscopy procedures performed for identified colorectal lesions (n=25,190)

- $\checkmark$  Cases of emergency colonoscopy procedures (n=1,873)
- ✓ Cases of colonoscopy procedures performed for participants with inflammatory bowel disease (n=9,910)

#### 129,065 cases of colonoscopy procedures analyzed

#### ADR (based on pathological diagnoses): 32.7% (95%CI: 32.5–33.0)







Ref) Kawamura T, Sekiguchi M, et al. Dig Endosc. 2023; 35: 615-24. Kawamura T, Sekiguchi M, et al. Dig Endosc. 2024; 36: 51-8.

186,293 cases of colonoscopy procedures performed for the study participants aged  $\geq$ 20 years at the eight participating institutions between April 2010 and March 2020 in the J-SCOUT study

Exclusion (with overlap in the following conditions)

 $\checkmark$  Cases of colonoscopy procedures performed within six months after the prior colonoscopy (n=31,533)  $\checkmark$  Cases of colonoscopy procedures performed for identified colorectal lesions (n=25,190)

- $\checkmark$  Cases of emergency colonoscopy procedures (n=1,873)
- ✓ Cases of colonoscopy procedures performed for participants with inflammatory bowel disease (n=9,910)

#### 129,065 cases of colonoscopy procedures analyzed

# ADR (based on pathological diagnoses): 32.7% (95%CI: 32.5–33.0)

#### Underestimated value

The Japanese guidelines allow diminutive benign adenomas <5mm to be left unresected (with the diagnosis)</p> Ref) Saito Y,---, Sekiguchi M, ---, et al. Colonoscopy screening and surveillance guidelines. Dig Endosc. 2021; 33: 486-519. using magnifying IEE). Sekiguchi M, et al. Am J Gastroenterol. 2019; 114: 964-973.

Due to relatively easy access to colonoscopies in Japan, polyps may not be removed at the time of examination and left for treatment on another day.







Ref) Kawamura T, Sekiguchi M, et al. Dig Endosc. 2023; 35: 615-24. Kawamura T, Sekiguchi M, et al. Dig Endosc. 2024; 36: 51-8.

186,293 cases of colonoscopy procedures performed for the study participants aged  $\geq$ 20 years at the eight participating institutions between April 2010 and March 2020 in the J-SCOUT study

Exclusion (with overlap in the following conditions)

 $\checkmark$  Cases of colonoscopy procedures performed within six months after the prior colonoscopy (n=31,533)  $\checkmark$  Cases of colonoscopy procedures performed for identified colorectal lesions (n=25,190)

- $\checkmark$  Cases of emergency colonoscopy procedures (n=1,873)
- ✓ Cases of colonoscopy procedures performed for participants with inflammatory bowel disease (n=9,910)

#### 129,065 cases of colonoscopy procedures analyzed

Exclusion (with overlap in the following conditions) ✓ Cases of colonoscopy procedures performed for unknown indications Cases of colonoscopies from 4 hospitals that had a policy of leaving adenomas <5 mm or usually not performing polypectomy on site</p>

47,705 cases of colonoscopy procedures analyzed









Ref) Kawamura T, Sekiguchi M, et al. Dig Endosc. 2023; 35: 615-24. Kawamura T, Sekiguchi M, et al. Dig Endosc. 2024; 36: 51-8.

186,293 cases of colonoscopy procedures performed f at the eight participating institutions between April 20

Exclusion (with overlap in the following conditions)

Cases of colonoscopy procedures performed within six mont

- ✓ Cases of colonoscopy procedures performed for identified co
- $\checkmark$  Cases of emergency colonoscopy procedures (n=1,873)
- ✓ Cases of colonoscopy procedures performed for participants

#### 129,065 cases of colonoscopy procedures analyzed

Exclusion (with overlap in the following conditions) Cases of colonoscopy procedures performed for unknown in ✓ Cases of colonoscopies from 4 hospitals that had a policy of

47,705 cases of colonoscopy procedures analyzed

7,705 1,339 3434	38.3 38.1 42.2 30.0	(37.8, 38.7 (37.2, 39.0 (41.1, 43.2 (28.5, 31.6
1,339 3434	38.1 42.2 30.0	(37.2, 39.0 (41.1, 43.2 (28.5, 31.6
1,339 3434	38.1 42.2 30.0	(37.2, 39.0 (41.1, 43.2 (28.5, 31.6
3434	42.2 30.0	(41.1, 43.2 (28.5, 31.6
3434	42.2 30.0	(41.1, 43.2
3434	42.2 30.0	(41.1, 43.2)
3434	30.0	(28.5, 31.6
		(,,
4969	25.5	(24.3, 26.7
4889	34.2	(32.9, 35.6
8687	46.2	(45.2, 47.3
5212	39.9	(38.6, 41.3
	4889 8687 5212 ; CI, con	4889 34.2 8687 46.2 5212 39.9 ; CI, confidence in







#### J-SCOUT Study Re

Ref) Kawamura T, Sekiguchi M, et al. Dig Endosc. 2023; 35: 615-24. Kawamura T, Sekiguchi M, et al. Dig Endosc. 2024; 36: 51-8.

In the setting in which "diagnose-and-do-not-resect" strategy and "resect-and-discard" strategy are allowed for diminutive benign adenomas, the correct evaluation of "pathological" ADR is difficult.

#### Proposal of "endoscopic ADR" (using (magnifying) IEE))

Strong correlation between pathological ADR and endoscopic ADR confirmed in institutions where all neoplastic polyps were removed non site during colonoscopies









## 1. Current Situation of CRC screening and Colonoscopy in Asia

### 2. Possibly Important Factors for Colonoscopy Quality from the Asian (Japanese) perspective



## **Detection of Flat Lesions**





## Flat Lesions: Laterally Spreading Tumor (LST)

### LST-G (granular type)



Homogeneous type (LST-GH)

### LST-NG (nongranular type)



Flat-elevated-type



Nodular mixed-type (LST-GM)



**Pseudo-depressed type** 

Ref) Digestive Endosc 2020; 32: 219-39



## Japan Polyp Study (JPS)

**Multicenter Randomized Control Trial** (conducted at 11 Participating Centers)

Courtesy of Prof. Takahisa Matsuda



### JPS Study Design





patients (40-69 yrs)

#### Reason for Referral to the JPS

- Positive FIT: 35%  $\bullet$
- Postpolypectomy surveillance: 20%
- Endoscopic treatment: 17%
- Symptoms: 12%
- Screening: 11%
- Others: 5%



Ref) Matsuda T, Fujii T,---, Sekiguchi M,---, Yoshida S, et al. Gut 2020; 70: 1469–78.









#### **Characteristics of Metachronous Advanced Neoplasia** (29 ANs in 28 Patients)



#### Rt-colon: 45%

Lt-colon: 38%

#### Rectum: 17%

#### Pathology

- Invasive Cancer: 1 (3.4%)
- High-grade dysplasia: 13 (44.8%)
- Low-grade dysplasia  $\geq$  10 mm: 15 (51.7%)

Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan

#### Morphology









Ref) Sano Y, Hotta K, Matsuda T,---, Sekiguchi M,---, Yoshida S, et al. Clin Gastroenterol Hepatol. 2024; 22: 542-51.







#### **Metachronous Advanced Neoplasia Detected after Two-round Colonoscopy**

#### Location

#### Rt-colon: 57%

#### Lt-colon: 30%

#### Rectum: 13%

Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan

(77ANs in 71 Pts) Morphology NPCRNs: 60% (46/77) LST-NG: 67%

#### Pathology

- Low-grade dysplasia: 36 (47%)
- High-grade dysplasia: 37 (48%)
- T1: 2 (2.6%), >T2: 2 (2.6%)



## **Detection of Flat Lesions**

## FDR (Flat Adenoma Detection rate)

"--- the clinical importance of superficial tumors has recently been recognized in Europe and the US. The clinical importance of FDR must be disseminated from Japan as well." Ref) JGES. Colonoscopy screening and surveillance guidelines. Dig Endosc. 2021; 33: 486-519.

#### Potential usefulness of IEE and AI for detection of flat adenomas

CADe (WISE VISION, NEC)









Ref) Hassan C, et al. Gastrointest Endosc. 2021; 93: 77-85. Atkinson NSS, et al. Gastroenterology. 2019; 157: 462-471. etc.



## **Other Factors**

## (Sessile) Serrated Lesion Detection Rate

interval cancer and PCCRC

Ref) Sekiguchi M, et al. C-DETECT study. Dig Endosc 2024

#### ✓ Not necessarily correlated with ADR in endoscopists

Ref) Mizuguchi Y, Kawamura T, Sekiguchi M, et al. DDW 2024.

	RAF and R
Genetic find	dings
BRAF	(+)
mutation	(—) Unknov
RAS	(+)
mutation	(—)
	Luchana

### Scope Insertion Time

Association between scope insertion time and ADR per endoscopist

Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan

#### ✓ Higher proportions of right-sided lesions, female patients, and BRAF mutations in FIT-

AS	mutations	in	metastatic	colorectal	cancers	with	different	intervals	from	previous	examinations
----	-----------	----	------------	------------	---------	------	-----------	-----------	------	----------	--------------

	F	FIT-interval cancer and PCCRC Others						
	Total $(n = 27)$	<1 year after FIT— $(n = 17)$	<3 years after CS $(n = 10)$	Total $(n = 359)$	<1 year after FIT+ and no CS ( <i>n</i> = 19)	(/		
	3 (12.0%)	2 (11.8%)	1 (12.5%)	10 (3.1%)	0 (0.0%)	1		
vn	22 (88.0%) 2	15 (88.2%) 0	7 (87.5%) 2	311 (90.9%) 38	0	29		
	12 (48.0%) 13 (52.0%)	8 (47.1%) 9 (52.9%)	4 (50.0%) 4 (50.0%)	153 (47.7%) 168 (52.3%)	7 (36.8%) 12 (63.2%)	14 15		
vn	2	0	2	38	0	3		

fecal immunochemical test; PCCRC, postcolonoscopy colorectal cancer.

Ref) Kawamura T, Sekiguchi M, et al. Dig Endosc. 2024; 36: 51-8. Sekiguchi M, et al. J Gastroenterol Hepatol. 2022; 37: 2120-30. etc.





## Summary

Colonoscopy is widely used for CRC screening in Asia.

Monitoring and feedback systems of colonoscopy quality are being developed (particularly, in Taiwan), leading to the improvement in the quality. However, there is much room for improvement.

Detection of flat lesions (particularly, LST-NG) is worthy of attention.





## Acknowledgements



Dr. Wen-Feng Hsu (Taiwan)



Prof. Han-Mo Chiu (Taiwan)







Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan





Prof. Chang Mo Moon (South Korea)

Dr. Jonathan Lee Wei Jie (Singapore)

Dr. Supakij Khomvilai (Thailand)



Prof. Takahisa Matsuda (Japan)



# **END02024**

#### **Connecting the World of Endoscopy** 4<sup>th</sup> World Congress of GI Endoscopy

Incorporating: International Digestive Endoscopy Network (IDEN)







#### Seoul, Korea · July 4-6, 2024 COEX Convention & Exhibition Center



Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan

#### **PROGRAM HIGHLIGHTS:**

7 scientific tracks for three days presenting best research from around the world 2 full days of live demonstrations from renowned centres in China, India, Korea and Thailand

**6** joint symposia with partner societies

WEO Video World Cup and e-poster sessions Joint industry exhibition together with **IDEN** 

2 days of hands-on training with international experts and live discussion More than **20** scientific symposia and **4** distinguished lectures

#### REGISTER NOW!

worldendo2024.org

SCIENTIFIC PARTNERS















Sekiguchi M, Endoscopy Division/Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan

# World Endoscopy Organization

